Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies
- PMID: 34041740
- DOI: 10.1111/bjh.17551
Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies
Keywords: chimaeric antigen receptor-T cells; immunomonitoring; mass cytometry.
References
-
- June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64-73.
-
- Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317-25.
-
- Shah NN, Fry T. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372-85.
-
- Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563-71.
-
- Du M, Hari P, Hu Y, Mei H. Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomarker. 2020;8:1-13.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources